Tobevibart + Elebsiran + Bulevirtide
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Viral Hepatitis
Conditions
Viral Hepatitis
Trial Timeline
Jul 30, 2025 → Jul 1, 2031
NCT ID
NCT07128550About Tobevibart + Elebsiran + Bulevirtide
Tobevibart + Elebsiran + Bulevirtide is a phase 3 stage product being developed by Vir Biotechnology for Viral Hepatitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07128550. Target conditions include Viral Hepatitis.
What happened to similar drugs?
1 of 5 similar drugs in Viral Hepatitis were approved
Approved (1) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07142811 | Phase 2 | Active |
| NCT07128550 | Phase 3 | Recruiting |
Competing Products
17 competing products in Viral Hepatitis